DE3751922T2 - Herstellung und Verwendung von IL-6 - Google Patents

Herstellung und Verwendung von IL-6

Info

Publication number
DE3751922T2
DE3751922T2 DE3751922T DE3751922T DE3751922T2 DE 3751922 T2 DE3751922 T2 DE 3751922T2 DE 3751922 T DE3751922 T DE 3751922T DE 3751922 T DE3751922 T DE 3751922T DE 3751922 T2 DE3751922 T2 DE 3751922T2
Authority
DE
Germany
Prior art keywords
production
hematopoietins
deficiencies
peptide
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751922T
Other languages
English (en)
Other versions
DE3751922D1 (de
Inventor
Steven Clark
Gordon Wong
Paul Schendel
John Mccoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27367237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3751922(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE3751922D1 publication Critical patent/DE3751922D1/de
Application granted granted Critical
Publication of DE3751922T2 publication Critical patent/DE3751922T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
DE3751922T 1986-07-08 1987-07-07 Herstellung und Verwendung von IL-6 Expired - Fee Related DE3751922T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88320786A 1986-07-08 1986-07-08
US88590586A 1986-07-15 1986-07-15
US4795787A 1987-05-08 1987-05-08

Publications (2)

Publication Number Publication Date
DE3751922D1 DE3751922D1 (de) 1996-11-14
DE3751922T2 true DE3751922T2 (de) 1997-04-03

Family

ID=27367237

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3751922T Expired - Fee Related DE3751922T2 (de) 1986-07-08 1987-07-07 Herstellung und Verwendung von IL-6
DE3751406T Revoked DE3751406T2 (de) 1986-07-08 1987-07-07 Herstellung und Verwendung von nicht-glycosiliertem IL-6.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3751406T Revoked DE3751406T2 (de) 1986-07-08 1987-07-07 Herstellung und Verwendung von nicht-glycosiliertem IL-6.

Country Status (18)

Country Link
EP (2) EP0574955B1 (de)
JP (1) JP2664698B2 (de)
KR (1) KR960013601B1 (de)
AT (2) ATE143811T1 (de)
AU (1) AU615630B2 (de)
CA (1) CA1341355C (de)
DE (2) DE3751922T2 (de)
DK (1) DK173279B1 (de)
ES (1) ES2006776A6 (de)
GR (1) GR871027B (de)
IE (1) IE67035B1 (de)
IL (1) IL83137A (de)
MY (1) MY102865A (de)
NO (1) NO176665C (de)
PL (1) PL159182B1 (de)
PT (1) PT85285B (de)
SK (1) SK279144B6 (de)
WO (1) WO1988000206A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554513A (en) * 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
US5510472A (en) * 1979-11-21 1996-04-23 Yeda Research And Development Co. Ltd. Production of recombinant human interferon-beta2
EP0645452A1 (de) * 1985-10-14 1995-03-29 Yeda Research And Development Co. Ltd. Menschliche Interferon-beta 2A und Interferon-beta 2B, Vektoren die ihre kodierende Gene enthalten, Zellinie die diese Interferon produzieren und Verwendung davon in einem Medikament
JP2648860B2 (ja) * 1986-05-08 1997-09-03 イエダ リサーチ アンド デベロップメント コンパニー リミテッド ヒトインターフエロン−β２Ａ及びヒトインターフエロン−β２Ｂ、該インターフエロンをコードする遺伝子を含むベクター、該インターフエロンを産生するセルライン及び該インターフエロンの医薬品としての用途
EP0585957A1 (de) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Rekombinanter B-Zell-Differenzierungsfaktor
JP2676336B2 (ja) * 1986-08-06 1997-11-12 忠三 岸本 ヒトｂ細胞分化因子の遺伝子
JPS6356291A (ja) * 1986-08-27 1988-03-10 Chuzo Kishimoto リコンビナントｂｃｄｆ
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
IL85204A0 (en) * 1988-01-26 1988-07-31 Yeda Res & Dev Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
JPH022353A (ja) * 1988-03-10 1990-01-08 Tosoh Corp ヒトｂ細胞分化因子の製造法
JPH022354A (ja) * 1988-03-31 1990-01-08 Tosoh Corp ヒトｂ細胞分化因子の製造法
GB2217327B (en) * 1988-04-12 1992-01-29 British Bio Technology Synthetic interleukin-6 gene
US5646015A (en) * 1988-08-31 1997-07-08 Astra Ab Excretion of heterologous proteins from E. coli
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
JPH0372429A (ja) * 1988-10-07 1991-03-27 Chugai Pharmaceut Co Ltd 血小板減少症の治療剤
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
JPH0331215A (ja) * 1989-06-27 1991-02-12 Ajinomoto Co Inc 制癌療法支持剤
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
EP0547223B1 (de) * 1990-08-31 1996-10-16 Santen Pharmaceutical Co., Ltd. Arznei gegen hornhautbeschädigungen
ATE210150T1 (de) * 1991-04-18 2001-12-15 Toray Industries Verfahren zur herstellung von interleukin-6 zusammensetzungen
US5641868A (en) * 1991-04-18 1997-06-24 Toray Industries, Inc. Interlekin-6 compositions, and a production process thereof
ZA924674B (en) * 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5338833A (en) * 1992-07-23 1994-08-16 The University Of North Carolina At Chapel Hill Carboxy terminal IL-6 muteins
US5338834A (en) * 1993-01-26 1994-08-16 Allelix Biopharmaceuticals Inc. Ultrapure human interleukin-6
EP0661057A4 (de) * 1993-06-08 1997-09-03 Ajinomoto Kk Beschleuniger der proliferation hämatogoetischer zellen.
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US5641657A (en) * 1994-05-19 1997-06-24 Human Genome Sciences, Inc. DNA encoding an interleukin-6 splice variant
EP0721780A3 (de) * 1994-12-16 1997-12-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Mittel zur Förderung von Plättchen und/oder Leucozytenherstellung
US7968696B1 (en) * 1996-07-19 2011-06-28 Behring Diagnostics Gmbh Viral interleukin-6
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US7479540B1 (en) 2003-12-22 2009-01-20 Chandan Prasad Adipomodulin and related molecules and methods
CA2597795A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
EP0645452A1 (de) * 1985-10-14 1995-03-29 Yeda Research And Development Co. Ltd. Menschliche Interferon-beta 2A und Interferon-beta 2B, Vektoren die ihre kodierende Gene enthalten, Zellinie die diese Interferon produzieren und Verwendung davon in einem Medikament
EP0585957A1 (de) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Rekombinanter B-Zell-Differenzierungsfaktor

Also Published As

Publication number Publication date
JPH01503354A (ja) 1989-11-16
IL83137A (en) 1995-05-26
MY102865A (en) 1993-03-31
DE3751922D1 (de) 1996-11-14
EP0574955B1 (de) 1996-10-09
GR871027B (en) 1987-11-02
PT85285A (en) 1987-08-01
KR960013601B1 (ko) 1996-10-09
ES2006776A6 (es) 1989-05-16
DE3751406T2 (de) 1995-12-21
EP0316319A4 (de) 1989-08-09
ATE124959T1 (de) 1995-07-15
IE871726L (en) 1988-01-08
EP0316319A1 (de) 1989-05-24
ATE143811T1 (de) 1996-10-15
PL159182B1 (pl) 1992-11-30
JP2664698B2 (ja) 1997-10-15
SK515087A3 (en) 1998-07-08
DK121788A (da) 1988-03-07
EP0316319B1 (de) 1995-07-12
DE3751406D1 (de) 1995-08-17
DK121788D0 (da) 1988-03-07
DK173279B1 (da) 2000-06-05
PT85285B (pt) 1990-03-30
NO880929L (no) 1988-03-02
IE67035B1 (en) 1996-02-21
PL266680A1 (en) 1988-07-07
AU615630B2 (en) 1991-10-10
CA1341355C (en) 2002-04-09
WO1988000206A1 (en) 1988-01-14
EP0574955A1 (de) 1993-12-22
KR880701736A (ko) 1988-11-04
NO176665C (no) 1995-05-10
NO176665B (no) 1995-01-30
AU7696287A (en) 1988-01-29
SK279144B6 (sk) 1998-07-08
NO880929D0 (no) 1988-03-02

Similar Documents

Publication Publication Date Title
DE3751922D1 (de) Herstellung und Verwendung von IL-6
DE68929167D1 (de) Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ES2052580T3 (es) Nuevas formas de factor-1 estimulante de colonias.
DE3650751T2 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
ATE78399T1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
DE69334211D1 (de) Multidrug resistenz gen
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
PT84605A (de) Verwendung von substituierten n-trichlormethylthiodicarboximiden in kombination mit n,n:-substituierten bis-(2,4-diamino-s-triazin-6-yl)-oligosulfiden in vulkanisierbaren kautschukmischungen und derartige kautschukmischungen
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
DE68924222T2 (de) Megakaryocytopoietin, seine Herstellung und Benutzung.
PT84602A (de) Verwendung von substituierten n-trichlormethylthiohydantionen in kombination mit bis-(2,4-diamino-s-triazin-6-yl)-oligosulfiden in vulkanisierbaren kautschukmischungen und derartige kautschukmischungen
ATE92333T1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
Watkins et al. Further characterization of A T-cell growth factor from the frog, Xenopus
ATE141104T1 (de) Gentechnische herstellung von protein pp 15.
SU1475058A1 (ru) Днище гидросамолета

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US

8339 Ceased/non-payment of the annual fee